Acumen Q3 loss $3.9M, cash $229.9M; ACU193 Phase 1 trial enrolling

Acumen Pharmaceuticals, Inc.

2022-Q3 EPS reported -$7.00

Net loss $3.9M (Q3), $92.3M (9M) including $80.3M non-cash fair-value charges from preferred stock and warrant liabilities.
Cash and marketable securities $229.9M at Sep 30, 2021 (vs. $43.8M at Dec 2020); IPO net proceeds $168.6M in July 2021.
R&D expenses $1.8M (Q3), G&A $2.1M; loss from operations $3.9M.
INTERCEPT-AD Phase 1 trial of ACU193 (anti-AβO antibody) dosed first patient; sentinel safety review passed.
Topline data expected by end of 2022; COVID-19 Delta variant delayed site activation but recruitment ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.